“Any directors that support such patently anti-shareholder maneuvers cannot be trusted to credibly evaluate potentially value-maximizing alternatives versus management’s perpetually ineffective plans,” he wrote in a letter that details the nominations.

Kohl’s said: “Macellum’s effort to take control of the board is unjustified and counterproductive” and called the hedge fund’s claim that the board isn’t able to review sales opportunities “groundless.” It also said Macellum’s comments on the shareholder rights plan, also called a poison pill, are “misleading.”

Duskin has said privately that Kohl’s 14-member board is too large and too entrenched to make the changes needed to push up the company’s lagging share price. He also said that the company needs to have a shareholder on the board and he nominated himself along with nine others with expertise in retail and investment banking.

“Given the growing list of issues and red flags in the boardroom, we believe substantial and urgent change is needed,” Duskin wrote.

This marks the second time that Macellum has nominated directors at Kohl’s after it was part of a consortium that sought to replace nine board members last year.

The investors agreed to drop that challenge when Kohl’s expanded its 11-member board by three directors in 2021.

Reuters reported in December that Macellum was planning to nominate directors and in January that the firm was pressing Kohl’s for at least one board seat and a public statement that the company is reviewing strategic alternatives.

Last week, Kohl’s rebuffed two takeover offers that would have valued the company at roughly $9 billion.